Nkarta (NKTX) Interest & Investment Income (2019 - 2026)
Nkarta (NKTX) posted quarterly Interest & Investment Income of $2.8 million for Q1 2026, down 35.15% year-over-year from $4.4 million in Q1 2025, and down 13.9% quarter-over-quarter from $3.3 million in Q4 2025.
Nkarta (NKTX) Interest & Investment Income (2019 - 2026) Analysis & Trends
Nkarta's Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 35.15% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $14.0 million (down 31.75% YoY), while the FY2025 annual figure was $15.5 million, down 19.79% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.8 million, down from $3.3 million in the prior quarter.
- The five-year high for Interest & Investment Income was $5.7 million in Q2 2024, with the low at $112000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $3.5 million (2023), against an average of $3.4 million.
- The sharpest annual moves came in 2023 and 2026: Interest & Investment Income surged 2993.75% in 2023, then slumped 35.15% in 2026.
- Nkarta's Interest & Investment Income stood at $2.9 million in 2022, then increased by 19.58% to $3.5 million in 2023, then surged by 41.61% to $4.9 million in 2024, then plunged by 32.65% to $3.3 million in 2025, then decreased by 13.9% to $2.8 million in 2026.
- Business Quant data shows NKTX's Interest & Investment Income at $2.8 million in Q1 2026, $3.3 million in Q4 2025, and $3.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 2.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.54 Mn |
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Dec 31, 2024 | 4.89 Mn |
| Sep 30, 2024 | 5.45 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 3.25 Mn |
| Dec 31, 2023 | 3.46 Mn |
| Sep 30, 2023 | 3.62 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 3.47 Mn |
| Dec 31, 2022 | 2.89 Mn |
| Sep 30, 2022 | 1.90 Mn |
| Jun 30, 2022 | 686,000.00 |
| Mar 31, 2022 | 112,000.00 |
| Dec 31, 2021 | -448,000.00 |
| Sep 30, 2021 | 81,000.00 |